Systemic inflammation, often called chronic low-grade inflammation, can persist for long periods without apparent symptoms making it difficult to identify and manage. Common signs of inflammation, such as fatigue, gastrointestinal disorders, skin changes, and cognitive issues, may often be mistaken for other conditions leaving many patients without a precise diagnosis and appropriate treatment.
Chronic systemic inflammation contributes to the vast majority of chronic health conditions, including autoimmune diseases, type 2 diabetes, hormone imbalances, and other serious health issues. As awareness of its role in disease pathogenesis grows, an expanding body of research furthers our understanding of the numerous and intricate connections between inflammation and aspects of health.
It is difficult, if not dangerous, to predict the future. But trends and good data can point the way toward possibilities and probabilities. There is momentum building in our understanding of Chronic Inflammatory Response Syndrome (CIRS), and the science has grown exponentially in the past 18 months thanks to transcriptomics. This new knowledge is sweeping our efforts forward in a more defined direction while we hone our understanding of the disease. The future is coming into focus.
There are also larger moving parts within the general CIRS practitioner community and even external social and market forces that seem to be creating a set of likely outcomes that are both exciting and important.
Increasing life expectancy has led to silently progressive neurodegenerative disorders becoming more prominent worldwide. In the case of neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, the urgent need for targeted and effective treatments is more significant than ever.
Major technological advancements have spurred research and development in the biotechnology industry, leading to the discovery of novel therapeutic platforms that can target the root cause of diseases.
With the help of advanced technologies such as artificial intelligence, gene editing, and precision medicine, biotech companies are now better equipped to develop new treatment strategies. One promising approach gaining significant attention in recent years involves targeting the overactive immune system and reducing systemic inflammation to mitigate the detrimental effects of neuroinflammation.